Numerical methods for the evaluation of individual bioequivalence criteria

被引:1
|
作者
Kimanani, EK [1 ]
Lavigne, J [1 ]
Potvin, D [1 ]
机构
[1] Phoenix Int Life Sci, Biometr & Pharmacokinet R&D, Phoenix Int Life Sci, Quebec City, PQ H4R 2N6, Canada
关键词
D O I
10.1002/1097-0258(20001030)19:20<2775::AID-SIM545>3.3.CO;2-7
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
The evaluation of individual bioequivalence (IBE) by bootstrap resampling using common statistical software, for example SAS, is extremely time consuming. In this article, an estimation procedure that can be implemented in a high level language with the same degree of accuracy as SAS is described. The necessary parameter estimating equations under both least square (LSE) and restricted maximum likelihood (REML) methods are given. The algorithms used to numerically compute these values are outlined and tested in FORTRAN, on several simulated data sets and shown to reproduce SAS results with at least 10(-3) precision. More importantly, the REML bootstrap algorithm reduces the time taken in SAS by a factor of 20. Secondary results indicate that LSE and REML parameter estimates are similar for mild unbalancedness. PROC MIXED, with unstructured (UN) and compound symmetry heterogeneous (CSH) variance structures give the same results except when the subject-by-treatment interaction variance, sigma(D)(2), is 0 in which case CSH significantly overestimates sigma(D)(2) and underestimates the within-treatment variances. It is concluded that bootstrap evaluation of IBE is efficiently done using either the LSE or REML algorithm in FORTRAN. Copyright (C) 2000 John Wiley & Sons, Ltd.
引用
收藏
页码:2775 / 2795
页数:21
相关论文
共 50 条
  • [21] Individual Bioequivalence Revisited
    Mei-Ling Chen
    Lawrence J. Lesko
    Clinical Pharmacokinetics, 2001, 40 : 701 - 706
  • [22] The basis for individual bioequivalence
    R. L. Williams
    R. N. Patnaik
    M-L. Chen
    European Journal of Drug Metabolism and Pharmacokinetics, 2000, 25 : 13 - 17
  • [23] Individual bioequivalence revisited
    Chen, ML
    Lesko, LJ
    CLINICAL PHARMACOKINETICS, 2001, 40 (10) : 701 - 706
  • [24] Average bioequivalence evaluation: General methods for pilot trials
    Pan, GH
    Wang, YB
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2006, 16 (02) : 207 - 225
  • [25] THE DEVELOPMENT OF EVALUATION CRITERIA FOR INDIVIDUAL EVENTS
    OLSON, CD
    SPHERES OF ARGUMENT, 1989, : 434 - 439
  • [26] Has the Time Come to Employ Population and Individual Bioequivalence for the Evaluation of Generics?
    Micheal, Francis
    Sayana, Mohanlal
    Prasad, Rajendra
    Motilal, Balamurali Musuvathi
    CURRENT DRUG METABOLISM, 2020, 21 (02) : 112 - 125
  • [27] An alternative definition of individual bioequivalence
    Longford, NT
    STATISTICA NEERLANDICA, 2000, 54 (01) : 14 - 36
  • [28] The bootstrap procedure in individual bioequivalence
    Shao, J
    Chow, SC
    Wang, B
    STATISTICS IN MEDICINE, 2000, 19 (20) : 2741 - 2754
  • [29] Individual bioequivalence - New concepts in the statistical assessment of bioequivalence metrics
    Patnaik, RN
    Lesko, LJ
    Chen, ML
    Wiliams, RL
    Balch, A
    Chan, K
    Machado, S
    Schuirmann, D
    Hauck, W
    Schall, R
    CLINICAL PHARMACOKINETICS, 1997, 33 (01) : 1 - 6
  • [30] ON BAYESIAN METHODS FOR BIOEQUIVALENCE
    SELWYN, MR
    HALL, NR
    BIOMETRICS, 1984, 40 (04) : 1103 - 1108